Skip to main content
High Melphalan Exposure Increases the Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Alpha-Beta T-Cell Depleted Haploidentical Transplantation.
Younger Children with Non-Malignant Disease Have Increased Incidence of Mixed Myeloid Chimerism After Allogeneic Hematopoietic Cell Transplantation with Busulfan-Based Conditioning.
The Pediatric Immunocompromised Critical Care Program: Getting Everyone in the Room.
Real-World Assessment of Patient Adherence to the Late Effects Screening Recommendations Among Hematopoietic Cell Transplantation Survivors.
Betibeglogene Autotemcel (Beti-cel) Gene Addition Therapy Results in Durable Hemoglobin A (HbA) Production with up to 10 Years of Follow-up in Participants with Transfusion-Dependent ß-Thalassemia.
Hematopoietic Cell Transplantation for Wiskott-Aldrich Syndrome - Impact of Age, Donor, and Infection: A Pidtc Report.
Younger Children Have Increased Mixed Myeloid Chimerism with Busulfan-Based Conditioning for Hematopoietic Cell Transplantation of Non-Malignant Disease.
Liberalizing Requirements for Hospital Proximity Post-CD19 CAR for Children with Low Burden B-ALL at Infusion.
High Exposure of Intravenous Alemtuzumab Is Associated with Increased Risk of Double-Stranded DNA Viral Infections in Patients with Non-Malignant Disease Undergoing Allogeneic HCT.
Fludarabine Pharmacokinetic-Model-Based Dosing Minimizes the Risk of Graft Rejection in Pediatric Patients Undergoing Mismatched Allogeneic Hematopoietic Cell Transplantation.